BR112022026420A2 - Composições biespecíficas direcionadas por her-2 e métodos para preparar e usar as mesmas - Google Patents
Composições biespecíficas direcionadas por her-2 e métodos para preparar e usar as mesmasInfo
- Publication number
- BR112022026420A2 BR112022026420A2 BR112022026420A BR112022026420A BR112022026420A2 BR 112022026420 A2 BR112022026420 A2 BR 112022026420A2 BR 112022026420 A BR112022026420 A BR 112022026420A BR 112022026420 A BR112022026420 A BR 112022026420A BR 112022026420 A2 BR112022026420 A2 BR 112022026420A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- preparing
- compositions
- polypeptides
- targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Containers Having Bodies Formed In One Piece (AREA)
- Dental Preparations (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
COMPOSIÇÕES BIESPECÍFICAS DIRECIONADAS POR HER-2 E MÉTODOS PARA PREPARAR E USAR AS MESMAS. A presente invenção se refere a polipeptídeos e métodos de produção e uso de tais polipeptídeos, que compreendem um construto de anticorpo biespecífico ligado covalentemente a um polipeptídeo recombinante estendido compreendendo um fragmento com código de barras liberável do referido polipeptídeo após digestão por uma protease e um segmento de liberação que pode ser clivado proteoliticamente em que a referida clivagem libera o construto de anticorpo biespecífico do polipeptídeo recombinante estendido.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063044301P | 2020-06-25 | 2020-06-25 | |
US202063077503P | 2020-09-11 | 2020-09-11 | |
US202063108783P | 2020-11-02 | 2020-11-02 | |
US202163166857P | 2021-03-26 | 2021-03-26 | |
US202163196408P | 2021-06-03 | 2021-06-03 | |
PCT/US2021/039006 WO2021263058A1 (en) | 2020-06-25 | 2021-06-24 | Her-2 targeted bispecific compositions and methods for making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022026420A2 true BR112022026420A2 (pt) | 2023-04-18 |
Family
ID=79281898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022026420A BR112022026420A2 (pt) | 2020-06-25 | 2021-06-24 | Composições biespecíficas direcionadas por her-2 e métodos para preparar e usar as mesmas |
Country Status (11)
Country | Link |
---|---|
US (2) | US20230322922A1 (pt) |
EP (1) | EP4172179A1 (pt) |
JP (1) | JP2023531494A (pt) |
KR (1) | KR20230041711A (pt) |
AU (1) | AU2021297984A1 (pt) |
BR (1) | BR112022026420A2 (pt) |
CA (1) | CA3182372A1 (pt) |
CO (1) | CO2023000247A2 (pt) |
IL (1) | IL298815A (pt) |
MX (1) | MX2022016387A (pt) |
WO (1) | WO2021263058A1 (pt) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016077505A2 (en) * | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
TW201930341A (zh) * | 2017-12-21 | 2019-08-01 | 美商亞穆尼克斯製藥公司 | 釋放片段及包含其之結合組合物 |
AU2019222666A1 (en) * | 2018-02-15 | 2020-09-03 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
JP2023501478A (ja) * | 2019-11-13 | 2023-01-18 | アミュニックス・ファーマシューティカルズ・インコーポレイテッド | バーコード化されたxtenポリペプチドおよびその組成物、ならびにその作製および使用方法 |
-
2021
- 2021-06-24 BR BR112022026420A patent/BR112022026420A2/pt unknown
- 2021-06-24 EP EP21829062.5A patent/EP4172179A1/en active Pending
- 2021-06-24 AU AU2021297984A patent/AU2021297984A1/en active Pending
- 2021-06-24 IL IL298815A patent/IL298815A/en unknown
- 2021-06-24 CA CA3182372A patent/CA3182372A1/en active Pending
- 2021-06-24 KR KR1020237002752A patent/KR20230041711A/ko unknown
- 2021-06-24 MX MX2022016387A patent/MX2022016387A/es unknown
- 2021-06-24 WO PCT/US2021/039006 patent/WO2021263058A1/en active Application Filing
- 2021-06-24 JP JP2022578997A patent/JP2023531494A/ja active Pending
-
2022
- 2022-12-10 US US18/064,253 patent/US20230322922A1/en active Pending
-
2023
- 2023-01-11 CO CONC2023/0000247A patent/CO2023000247A2/es unknown
- 2023-10-25 US US18/494,007 patent/US20240076378A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023531494A (ja) | 2023-07-24 |
KR20230041711A (ko) | 2023-03-24 |
EP4172179A1 (en) | 2023-05-03 |
AU2021297984A1 (en) | 2023-02-23 |
IL298815A (en) | 2023-02-01 |
CA3182372A1 (en) | 2021-12-30 |
US20240076378A1 (en) | 2024-03-07 |
CO2023000247A2 (es) | 2023-01-26 |
US20230322922A1 (en) | 2023-10-12 |
MX2022016387A (es) | 2023-04-11 |
WO2021263058A1 (en) | 2021-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021003543A (es) | Polipeptidos de citocinas enmascaradas. | |
MX2020009824A (es) | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. | |
PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
EA202190889A1 (ru) | Клостридиальные нейротоксины, содержащие экзогенную петлю активации | |
PE20090763A1 (es) | Polipetidos, dominios variables de anticuerpos y antagonistas | |
PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
AR109871A1 (es) | Péptidos escindibles y proteínas insecticidas y nematicidas que los comprenden | |
BR112017009951A2 (pt) | composições conjugadas direcionadas de xten e métodos de sua produção | |
CR11193A (es) | Polipeptidos, dominios variables de anticuerpos y antagonistas | |
CL2008002861A1 (es) | Polipeptido aislado de m. ruminantium; vector, molecula conjugada y celula huesped que comprenden dicho polipeptido; anticuerpo o fragmento que se une al polipeptido; composicion farmaceutica que comprende la molecula conjugada; metodo para dirigir una celula metanogena para identificacion, aislamiento o inhibicion. | |
AR079633A1 (es) | Toxina clostridiana modificada de cadena unica, composicion farmaceutica que la comprende, molecula de polinucleotido que la codifica y metodo para producir dicha toxina | |
BR112013029525A8 (pt) | Proteínas de fusão terapêuticas | |
ATE458000T1 (de) | Zielgerichtete fusionsproteine für die krebstherapie | |
ECSP12011577A (es) | Produccion recombinante de péptidos | |
BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
CO2022016595A2 (es) | Nuevas proteinas de unión a repeticiones de anquirina y sus usos | |
ECSP077295A (es) | Sistemas y metodos para la produccion de proteinas | |
BR112022009217A2 (pt) | Polipeptídeos xten com código de barras e composições destes, e métodos para produzir e usar os mesmos | |
BR112022026420A2 (pt) | Composições biespecíficas direcionadas por her-2 e métodos para preparar e usar as mesmas | |
HN2003000406A (es) | Clinker y cemento blanco con alto contenido de azufre, usado como combustible | |
BRPI0512935A (pt) | processo para a preparação de aminoácido úteis na preparação de moduladores receptores de peptìdeo | |
BR112018072968A2 (pt) | peptídeos monolipidados resistentes às proteases | |
AR118355A1 (es) | Métodos de fabricación para producir composiciones de anticuerpos anti-tnf | |
BR112023022531A2 (pt) | Conjugados de fármacos e anticorpos anti-c-met | |
AR114481A1 (es) | Anticuerpos injertados con péptido natriurético auricular |